Baker McKenzie-Led Bayer To Buy Perfuse For Up To $2.45B
Pharmaceutical giant Bayer AG said Wednesday that it will buy Perfuse Therapeutics, a U.S. biopharma company, for up to $2.45 billion as it seeks a treatment for ocular diseases....To view the full article, register now.
Already a subscriber? Click here to view full article